The official quarterly newsletter of Georgetown University's Office of Technology Commercialization.
View this email in your browser

VP Corner

While summer beckons us to vacations and adventures, it is also a time of celebration of accomplishments. OTC offers congratulations to all of Georgetown University’s students who graduate this week (including our own, Jeff Genota, who received his MPS in Technology Management from Georgetown University). This has been a productive year for OTC. We honored our inventors in our fourth Patent Awards Ceremony; several of our licensed technologies entered clinical trials; and new products, including tissue typing kits, malware detection technology and cell culture research tools are being sold by companies who licensed Georgetown University technologies over the past several years.  We also signed a license this spring with Axovant Sciences that we hope will accelerate the development of certain potential therapies for neurodegenerative diseases (see article below).  

We wish everyone a safe and happy summer and we look forward to working with you in the future.

Claudia Cherney Stewart, Ph.D.
Vice President, Technology Commercialization

Commercial Update

Georgetown University Licenses Use of Tyrosine Kinase Inhibitors for Treatment of Neurodegenerative Diseases 

Georgetown University has exclusively licensed worldwide intellectual property (IP) rights to develop and commercialize uses of tyrosine kinase (TK) inhibitors for the treatment of neurodegenerative diseases to Axovant Sciences GmbH.  The application of TK inhibiting compounds for use in neurodegenerative diseases was discovered by a Georgetown University Medical Center (GUMC) researcher.
Georgetown holds an issued patent and several pending patent applications for the use of select TK inhibitors for the treatment of certain neurodegenerative diseases. Charbel Moussa, MBBS, PhD, scientific and clinical research director for GUMC’s Translational Neurotherapeutics Program, is the named inventor on the IP.

 “The mechanism by  which tyrosine kinase  inhibitors affect  neurodegenerative  disorders appears to  involve autophagy in  the clearance of  neurotoxic proteins  associated with neurodegenerative diseases,” explains Moussa, an assistant professor in GUMC’s Department of Neurology.
Moussa collaborated with Fernando Pagan, MD, director of the Movement Disorders Program at MedStar Georgetown University Hospital who is the principal investigator on a phase II, randomized, double-blind, placebo-controlled clinical trial, which launched earlier this year to evaluate the safety and tolerability of low doses of nilotinib, a tyrosine kinase inhibitor, in Parkinson’s disease. A second study also was launched for Alzheimer’s disease, on which R. Scott Turner, MD, PhD, director of GUMC Memory Disorders Program, is principal investigator.
“Our understanding of the autophagy process in neurodegenerative diseases represents the newest frontier of neurotherapeutic research and changes the paradigm on how we think about these diseases,” Moussa says.

Upcoming Events

Stay tuned for our future events in the Fall 2017!
Further information:
Visit or E-mail Jeremy Alexander 
2016-17 Highlights: Patent Awards Ceremony
Like our Page
Like our Page
Follow Us
Follow Us
Visit Us Online
Visit Us Online
Invention to Disclose? Click Here!

The Year in Review

2017 Patent Awards Ceremony

OTC held its biannual Patent Awards Ceremony in February to recognize achievements from the University community in innovation and commercialization. This year's theme focused on "An Insider's View to Commercializing Inventions". The Ceremony recognized 42 Georgetown faculty who are named inventors on issued patents during 2015 and 2016, and also recognized two Georgetown inventors, Ophir Frieder and Mark Maloof from the Department of Computer Science, for outstanding contributions to innovation and commercialization. Keynote speakers were Rachel King, founder and CEO of GlycoMimetics, a biotech company in Gaithersburg, MD, and Jim Myers, information systems Sector Vice President of Northrop Grumman. Northrop, a licensee of malware detection technology invented by Georgetown’s Dr. Marc Maloof, recently spun out the commercial cybersecurity company, BluVector, which has commercial rights to the Georgetown technology.  University leaders in attendance to honor inventors at the ceremony included Provost Robert Groves and Ed Healton, Executive Vice President for Health Sciences and Executive Dean of Georgetown University School of Medicine. 

Intellectual Property 101 for Students

Recognizing the increasing focus of innovation and entrepreneurship in courses for Georgetown students, OTC partnered with Duane Morris LLP in an "Invention to Innovation" (I2I) seminar in March. Attorneys Jonathan Cohen and Mark Comtois from Duane Morris joined OTC’s VP, Claudia Stewart and Georgetown University Counsel Paul Greco to provide a primer of intellectual property and its ownership for the Georgetown community. Special emphasis was on student-generated intellectual property, which led to lively discussion between the students and faculty in the audience and the speakers. OTC hosted similar I2Is throughout the year for the University community, covering topics such as conflict-of-interest management and collaborative partnerships with the National Cancer Institute.
2016-17 Highlights: Induction of Inventors to the National Academy of Inventors
2016-17 Highlights: Invention to Innovation Seminars (Todd Buck, Morgan Lewis)

Recently Granted U.S. Patents for Georgetown University*

  • U.S. Patent Number 9,483,640, System and Method for Deterring Malicious Network Attacks, granted to Thomas Clay Shields on Nov. 1, 2016.
  • U.S. Patent Number 9,489,495 System and Method for Detecting, Collecting, Analyzing and Communicating Event Related Information, granted to Peter C. Li on Nov. 8, 2016.
  • U.S. Patent Number 9,511,050, Methods and Compositions for Treating Cancer, granted to Jeffrey A. Toretsky and Aykut Uren on Dec. 6, 2016.
  • U.S. Patent Number 9,521,955, Subdural Electro-Optical Sensor, granted to Jian-Young Wu on Dec. 20, 2016.
  • U.S. Patent Number 9,522,908, Ezrin Inhibitors and Methods of Making and Using, granted to Peter C. Li and Jeffrey R. Collmann on Dec. 20, 2016.
  • U.S. Patent Number 9,529,974, System and Method for Detecting, Collecting, Analyzing and Communicating Event Related Information, granted to Peter C. Li on Dec. 27, 2016
  • U.S. Patent Number 9,545,388, Benzenetricarboxylic Acid and Methods of Use, granted to Maria Laura Avantaggiati on Jan. 17, 2017.
  • U.S. Patent Number 9,549,993, Specific Delivery of Toxins Conjugated with Antibodies to Activated Matriptase, granted to Michael D. Johnson and Chen-Yong Lin on Jan. 24, 2017
  • U.S. Patent Number 9,555,134, Manganese-Oxo Clusters as Contrast Agents for Magnetic Resonance Imaging, granted to Christopher Albanese and Edward R. Van Keuren on Jan. 31, 2017
  • U.S. Patent 9,562,258, Sequence-Specific Detection of Nucleotide Sequences, granted to Mark Danielsen and Kenneth L. Dretchen on Feb. 7, 2017
  • U.S. Patent Number 9,545,388, Targeting of EWS-FLI1 as Anti-Tumor Therapy, granted to Milton L. Brown, Jeffrey A. Toretksy, and Aykut Uren on Feb. 21, 2017.
  • U.S. Patent 9,601,697, Systems and Process for Forming Carbon Nanotube Sensors, granted to Makarand Paranjape on Mar. 21, 2017
  • U.S. Patent 9,603,844, Compositions and Methods for Treating Mammary Tumors, granted to Eliot M. Rosen on Mar. 28, 2017.
*Only Georgetown University inventors are listed.
Copyright © 2016 Georgetown University Office of Commercialization, All rights reserved.

Georgetown University | Office of Technology Commercialization | 3300 Whitehaven St . NW | Harris Building, Suite 1500 | Washington, DC 20057 | Phone: (202) 687-7424 |

unsubscribe from this list    update subscription preferences 

This email was sent to <<Email Address>>
why did I get this?    unsubscribe from this list    update subscription preferences
Georgetown University Office of Technology Commercialization · 3300 Whitehaven St NW · Suite 1500 · Washington, DC 20007 · USA

Email Marketing Powered by Mailchimp